Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Ghrelin: a link between ageing, metabolism and neurodegenerative disorders.

Stoyanova II.

Neurobiol Dis. 2014 Dec;72 Pt A:72-83. doi: 10.1016/j.nbd.2014.08.026. Epub 2014 Aug 27. Review.

2.

Role of metabolism in neurodegenerative disorders.

Procaccini C, Santopaolo M, Faicchia D, Colamatteo A, Formisano L, de Candia P, Galgani M, De Rosa V, Matarese G.

Metabolism. 2016 Sep;65(9):1376-90. doi: 10.1016/j.metabol.2016.05.018. Epub 2016 Jun 7. Review.

PMID:
27506744
3.

The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.

Tan L, Yu JT, Tan L.

J Neurol Sci. 2012 Dec 15;323(1-2):1-8. doi: 10.1016/j.jns.2012.08.005. Epub 2012 Aug 29. Review.

PMID:
22939820
4.

Ghrelin as a neuroprotective and palliative agent in Alzheimer's and Parkinson's disease.

Dos Santos VV, Rodrigues AL, De Lima TC, de Barioglio SR, Raisman-Vozari R, Prediger RD.

Curr Pharm Des. 2013;19(38):6773-90. Review.

PMID:
23530516
5.

Mitochondria and neurodegeneration.

Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M.

Biosci Rep. 2007 Jun;27(1-3):87-104. Review.

PMID:
17486441
6.

Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins.

Butterfield DA, Kanski J.

Mech Ageing Dev. 2001 Jul 15;122(9):945-62. Review.

PMID:
11348660
7.
8.

Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.

Chen JF, Chern Y.

Handb Exp Pharmacol. 2011;(200):267-310. doi: 10.1007/978-3-642-13443-2_10. Review.

PMID:
20859800
9.

Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.

Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S.

Ann N Y Acad Sci. 1999;893:154-75. Review.

PMID:
10672236
10.

Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders.

Cai H, Cong WN, Ji S, Rothman S, Maudsley S, Martin B.

Curr Alzheimer Res. 2012 Jan;9(1):5-17. Review.

11.

Neuroprotective properties of resveratrol and derivatives.

Richard T, Pawlus AD, Iglésias ML, Pedrot E, Waffo-Teguo P, Mérillon JM, Monti JP.

Ann N Y Acad Sci. 2011 Jan;1215:103-8. doi: 10.1111/j.1749-6632.2010.05865.x. Review.

PMID:
21261647
12.

P-gp transporter and its role in neurodegenerative diseases.

Rapposelli S, Digiacomo M, Balsamo A.

Curr Top Med Chem. 2009;9(2):209-17. Review.

PMID:
19200006
13.
14.
15.

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, Cardinali DP.

Neurotox Res. 2013 Apr;23(3):267-300. doi: 10.1007/s12640-012-9337-4. Epub 2012 Jun 28. Review.

PMID:
22739839
16.

Metabolomics of human brain aging and age-related neurodegenerative diseases.

Jové M, Portero-Otín M, Naudí A, Ferrer I, Pamplona R.

J Neuropathol Exp Neurol. 2014 Jul;73(7):640-57. doi: 10.1097/NEN.0000000000000091. Review.

PMID:
24918636
17.

Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer's disease.

Gahete MD, Córdoba-Chacón J, Kineman RD, Luque RM, Castaño JP.

Peptides. 2011 Nov;32(11):2225-8. doi: 10.1016/j.peptides.2011.09.019. Epub 2011 Oct 1. Review.

18.

Neuroprotective effects of leptin in the context of obesity and metabolic disorders.

Davis C, Mudd J, Hawkins M.

Neurobiol Dis. 2014 Dec;72 Pt A:61-71. doi: 10.1016/j.nbd.2014.04.012. Epub 2014 Apr 26. Review.

PMID:
24780498
19.

New therapeutic strategy for Parkinson's and Alzheimer's disease.

Esposito E, Cuzzocrea S.

Curr Med Chem. 2010;17(25):2764-74. Review.

PMID:
20586718
20.

Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.

Sas K, Robotka H, Toldi J, Vécsei L.

J Neurol Sci. 2007 Jun 15;257(1-2):221-39. Epub 2007 Apr 25. Review.

PMID:
17462670

Supplemental Content

Support Center